CDT Equity partners with QIMA to evaluate tapinarof combinations
CDT Equity Inc. said it has partnered with QIMA Life Sciences to evaluate proprietary tapinarof combinations in psoriasis and vitiligo using human patient skin.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.